Anser IFX
Use
Anser IFX is utilized for therapeutic drug monitoring of infliximab (IFX) and antibodies-to-infliximab (ATI) levels. It assists healthcare professionals in optimizing biologic treatments by measuring drug concentrations in serum, which is critical in assessing treatment efficacy and safety for patients being treated with infliximab.
Special Instructions
The Anser IFX test uses proprietary homogeneous mobility shift assay (HMSA) methods that provide reliable results without interference from detectable drug levels, unlike many solid-phase assays. It is validated against World Health Organization (WHO) standards for IFX.
Limitations
As a laboratory-developed test, Anser IFX has not been cleared or approved by the US FDA. Its analytical and clinical validation has been conducted under the CLIA framework. The test's reliability for patients treated with biosimilars is implied but not explicitly certified.
Methodology
Immunoassay (HMSA)
Biomarkers
Result Turnaround Time
3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2.0 mL
Minimum Volume
0.5 mL for Peds
Container
Serum Separator Tube or Red-Top Tube
Storage Instructions
Transport ambient or with a cold pack. Do not freeze.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |